DuPont posted 5.0% organic growth, 31% adjusted EPS growth, and stronger margins in Q3 2026, while raising full-year guidance. Valuation is reasonable on forward earnings, but execution and cyclical end-market risks remain.
DuPont de Nemours Inc (DD) merits a Buy rating for moderate-risk investors with a medium-term horizon. The thesis rests on three hard facts: third-quarter 2026 net sales reached $1.9B with 5.0% organic growth, adjusted EPS rose 31.0% year over year to $2.09, and management raised full-year 2026 adjusted EPS guidance to $7.47 to $7.52.
The business is improving at the operating level. Third-quarter operating EBITDA increased 8.0% to $469M, margin expanded 90 basis points to 25.1%, and transaction-adjusted free cash flow reached $341M with 121.0% conversion. Healthcare & Water Technologies produced a 30.4% EBITDA margin, while Diversified Industrials delivered 11.0% EBITDA growth and a 24.1% margin.
The counterweight is valuation and execution risk. DD trades at 38.0x trailing earnings, annual 2025 net income was negative $779M, and the company remains exposed to construction, automotive, packaging, input costs, and Middle East project delays. The forward P/E of 17.6x and PEG ratio of 0.8x provide a more balanced view, especially alongside the $12.92 free cash flow per share and 9.1% free cash flow yield.
DuPont de Nemours Inc is a technology-based materials and solutions company headquartered in Wilmington, Delaware. The company was incorporated in 2015, adopted the DuPont de Nemours name in June 2019, employs about 15,000 people, and serves customers across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
DD now operates through two segments: Healthcare & Water Technologies and Diversified Industrials. The structure is more focused after the Electronics business separated into Qnity Electronics on November 1, 2025, and after the Aramids business was sold on April 1, 2026. That portfolio reshaping reduced reported 2025 revenue to $6.85B from $12.39B in 2024, but it also left a business mix centered on engineered materials and application-specific solutions.
The company does not primarily compete through commodity volume. It sells materials, membranes, protective products, adhesives, engineered components, and process solutions that are often embedded in customer products or production systems. Medical devices, water treatment, aerospace, construction, automotive, and industrial applications place a premium on qualification, reliability, and technical support.
Healthcare & Water Technologies generated third-quarter 2026 sales of $865M, up 4.0% year over year and 4.0% organically. Segment operating EBITDA increased 7.0% to $263M, and margin expanded 80 basis points to 30.4%. Healthcare sales grew at a mid-single-digit organic rate, led by double-digit gains in personal protection and medical packaging.
Water Technologies grew at a low-single-digit organic rate, supported by industrial water and double-digit growth in semiconductor and specialty markets. Middle East disruptions reduced the reported pace. Excluding that region, water organic growth reached a mid-single-digit rate. The combination of healthcare growth and a 30.4% segment margin makes this DD's strongest current earnings engine.
Diversified Industrials generated about $1.0B of third-quarter sales, up 4.0% year over year on 5.0% organic growth. Operating EBITDA rose 11.0% to $242M, producing a 24.1% margin that was 140 basis points higher than the prior year. Building Technologies grew at a mid-single-digit organic rate in North America and Asia, while Industrial Technologies benefited from double-digit gains in aerospace and EV battery applications.
The two segments offer different risk profiles. Healthcare and water provide stronger margins and exposure to medical, biopharma, semiconductor, municipal, and industrial demand. Diversified Industrials adds aerospace and battery growth, but also carries greater exposure to construction, automotive, printing, packaging, and the industrial cycle.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Tyvek remains one of DD's most visible platforms. It serves protective apparel, medical packaging, and building envelopes. Management reported more conversions to Tyvek house wrap among national and large regional builders, along with broader bundle sales in multifamily construction. Tyvek with Renewable Attribution launched during the third quarter and retains the product's performance profile while addressing customer demand for lower-carbon material sourcing.
The water portfolio includes AMBERLITE ion exchange resins, FILMTEC reverse osmosis and nanofiltration elements, and ultrafiltration modules sold under the INGE and ITEGRATEC names. A new purification technology targets peptide therapeutics, including GLP-1 drugs, by supporting purity, yield, and production scale. DD also won a large containerized desalination project in Europe, the Middle East, and Africa using ultrafiltration modules designed to improve water output within a constrained footprint.
Vespel custom-engineered seals and shapes serve aerospace applications where wear resistance and thermal stability matter. Management identified aerospace revenue of about $300M, or roughly 3.0% of company revenue, with low-double-digit growth for Vespel and Tedlar. BETATECH thermal materials add exposure to EV battery thermal management, while MOLYKOTE lubricants and BETAFORCE and BETASEAL adhesives extend DD's industrial and automotive reach.
DD's competitive advantage is strongest in products that require technical qualification and application support. Medical packaging, filtration membranes, aerospace seals, protective materials, and engineered adhesives are not interchangeable with a generic chemical input. Customer validation and the cost of a process failure support repeat business and give DD room to compete on performance rather than price alone.
Management said the innovation portfolio's vitality index remained in the mid-30% range, with the portfolio mix about 60.0% replacement-oriented and 40.0% growth-oriented. The company aims to move closer to a 50.0% growth and 50.0% replacement mix. DD spends about 2.5% of sales on research and development, with investment assigned within the operating businesses rather than through a centralized R&D structure.
AI is becoming an operating tool rather than a presentation slide. Management said the time required to move an idea from stage zero to stage one fell from about three months to five days in two businesses using AI agents. DD also reported about 150 basis points of margin lift from replacement-focused innovation in the prior year, because product updates preserved differentiation while allowing lower raw-material inputs to be qualified.
DD operates in about 50 countries and manufactures in about 20 countries. That footprint supports customer proximity and regional supply, but it also exposes the company to transportation, energy, raw-material, labor, regulatory, and geopolitical disruptions. The 2025 10-K identifies third-party suppliers, plant outages, weather events, sanctions, trade restrictions, and transportation limitations as operating risks.
The current operating program is producing measurable gains. DD completed more than 20 Kaizen events in the third quarter, generated more than 2.0% net productivity, and improved on-time-in-full performance by more than 100 basis points for the third consecutive quarter. Management places current OTIF performance in the low 80s against a long-term target of 95.0%, leaving a sizable execution runway.
Pricing actions are also offsetting input costs. Management said full-year pricing now approaches $110M, compared with the previously discussed $90M. Of an approximately $30M third-quarter revenue beat, about $10M came from incremental price and $20M from volume. The company pushed about $15M of Middle East water project revenue into 2027, while raising full-year 2026 sales guidance to about $7.19B.
DD participates in several specialty materials markets rather than one consolidated end market. Third-party market studies place the global specialty chemicals market in a broad range of about $1.0T to $1.3T, with projected growth generally around 4.0% to 5.0% annually. The range reflects different definitions, but the common thread is a shift toward performance materials, technical services, and application-specific products.
DD's strongest market positions align with healthcare, water treatment, aerospace, semiconductor applications, protective materials, and EV battery systems. Third-quarter organic growth of 5.0% and full-year 2026 guidance for about 4.5% organic growth show that the focused portfolio is growing above the 2025 continuing-operations revenue base.
Customer research in the chemical industry points to rising value placed on product performance, delivery responsiveness, technical support, safer materials, and regulatory assistance. DD's medical, water, aerospace, and building portfolios address these requirements directly. The commercial advantage is strongest when the customer buys product qualification and process reliability along with the material itself.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Healthcare customers include medical-device manufacturers, pharmaceutical producers, bioprocessing companies, and buyers of personal protective materials. The third quarter produced double-digit organic gains in personal protection and medical packaging, while the new purification technology targets peptide therapeutics and GLP-1 manufacturing.
Water customers include industrial wastewater operators, municipalities, desalination projects, energy companies, semiconductor manufacturers, and life-science businesses. Water sales grew in industrial and semiconductor applications despite Middle East disruption, and DD said orders for large Middle East projects remained in hand even as project timing shifted.
Diversified Industrials serves national and regional builders, aerospace OEMs, automotive manufacturers, battery developers, packaging companies, printers, and industrial equipment users. Aerospace has stronger order visibility than many other DD businesses, with management describing a full order book at the start of quarters and years. Building Technologies has gained share through Tyvek conversions and broader multifamily bundle sales.
DD competes with different companies across its portfolio. Named competitors include 3M, Honeywell, Ecolab, Toray, Avient, Lanxess, Owens Corning, Kingspan, Teijin, Hydranautics, and Yantai in water, protection, building, and specialty materials. Aerospace, industrial, and adhesive markets add competition from large global materials suppliers and focused application specialists.
DD's advantage is portfolio breadth combined with focused application expertise. A water membrane business, an aerospace seal business, and a medical packaging business do not share the same cycle, but each benefits from qualification and technical support. The tradeoff is that DD lacks the clean single-theme profile of a pure-play water, aerospace, or healthcare materials company.
The competitive evidence is strongest in recent execution. DD's Building Technologies business held volume roughly flat while the broader market was described as down low-single digits, and Diversified Industrials expanded EBITDA margin by 140 basis points in the third quarter. Those results point to share gains and productivity, not merely a rising market tide.
DD's exposure to construction, automotive, packaging, and industrial activity creates cyclical risk. The 2025 business context recorded a 2.0% organic sales decline in Diversified Industrials, while first-quarter 2026 results still showed weakness in construction. By contrast, aerospace, healthcare, industrial water, semiconductor applications, and EV batteries provided the strongest growth in 2026.
The Middle East is a direct operating issue. DD pushed about $15M of water project revenue from 2026 into 2027 because of continued regional disruption. The company also cited a 1.0% currency headwind in the third quarter, while pricing actions were designed to offset higher input costs.
Longer-term demand is supported by water scarcity, semiconductor capacity, safer materials, and sustainability requirements. DD reported a 76.0% reduction in Scope 1 and Scope 2 emissions from its 2019 baseline, a 66.0% reduction in Scope 3 emissions from its 2020 baseline, and renewable sourcing for 50.0% of electricity. These efforts support customer qualification and product differentiation, although regulatory and litigation exposure remains a material risk for a historical materials company.
DuPont’s balance sheet earns a B+ as the company pairs solid cash generation with lingering leverage and execution risk after major portfolio reshaping.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q3 2026 sales rose to $1.9B and adjusted EPS climbed 31.0% to $2.09, with operating EBITDA margin expanding 90 basis points to 25.1%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted full-year 2026 adjusted EPS guidance to $7.47-$7.52 after a quarter of 5.0% organic growth and 121.0% free cash flow conversion.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →DD trades at 17.6x forward earnings and a 0.8x PEG, which looks more balanced against its 38.0x trailing P/E and 9.1% free cash flow yield.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →With a Buy recommendation and a fair value of $165, the report sees upside supported by stronger margins, raised guidance, and improving cash flow.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →DuPont has moved from portfolio repair toward operating execution. The evidence is visible in third-quarter organic growth of 5.0%, 90 basis points of EBITDA margin expansion, $341M of transaction-adjusted free cash flow, and another increase to 2026 guidance. Healthcare, water, aerospace, and industrial productivity are carrying the investment case.
The stock is not a deep-value purchase at $154.19. Its trailing valuation remains elevated, reported 2025 earnings were negative, and the business still depends on steady execution across cyclical markets. However, the 17.6x forward P/E, 0.8x PEG ratio, 9.1% free cash flow yield, repeated earnings beats, and $165.29 analyst consensus create a favorable medium-term setup.
The appropriate stance is Buy, with position sizing that reflects the gap between DD's improving operating profile and its still-incomplete earnings normalization. Continued margin gains, strong cash conversion, and growth in healthcare, water, aerospace, and battery applications can support shareholder returns. A failure to convert the current order book and productivity pipeline would weaken that case quickly.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
DuPont de Nemours, Inc. (DD) rises after reporting third-quarter results that topped estimates and lifting full-year guidance again. Stronger sales, higher adjusted EPS, and robust cash flow fueled the rally, while buybacks added support. The stock now trades near its 52-week high, raising the bar for new buyers.
Keith Kohl’s Angel Publishing promotion for Technology and Opportunity, The AI Survivors, names three companies that supposedly can outlast the AI bubble. We test the claim against their filings.
Staysail Series Trust (NYSE: BWLB) is expected to list on 2026-11-13, but the company has not disclosed a price range yet. This is an ETF trust registration, not a traditional operating-company IPO, so the usual revenue and earnings metrics are not available. The setup favors investors who want a new Brandywine-branded ETF lineup, while the key watch item is how the funds are structured and whether the market wants another active ETF platform.